The abstract is read at the publisher; the summary is JClub's.
In 32 patients with HR+/HER2+ advanced breast cancer and measurable brain metastases, confirmed CNS-ORR reached 58.6% (95% CI 40.7–74.5) on palbociclib, fulvestrant, trastuzumab, and pyrotinib.
- Why it matters: Prospective systemic treatment data for HR+/HER2+ advanced breast cancer with brain metastases are limited, despite a high risk of CNS spread and the need for chemotherapy-sparing options.
- What they did: In a multicenter, single-arm phase 2 trial, patients received palbociclib, fulvestrant, trastuzumab, and pyrotinib until progression, unacceptable toxicity, or death, with confirmed central nervous system objective response rate as the primary endpoint.
- The result: Among 29 response-evaluable patients, overall ORR was 62.1% (95% CI 44.0–77.3), median CNS-PFS was 9.6 months, median overall PFS was 12.3 months, and grade ≥3 diarrhea (37.5%), neutropenia (28.1%), and leukopenia (15.6%) were manageable with no treatment-related deaths.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.